Daratumumab

Adult: As monotherapy in relapse or refractory case or in combination with lenalidomide and dexamethasone (4-week cycle regimen): For weeks 1-8: 16 mg/kg once weekly; for weeks 9-24: 16 mg/kg every 2 weeks (total of 8 doses); for weeks 25 onwards: 16 mg/kg every 4 weeks until disease progression. In combination with bortezomib and dexamethasone (3-week cycle regimen): For weeks 1-9: 16 mg/kg once weekly; for weeks 10-24: 16 mg/kg every 3 weeks (total of 5 doses); for weeks 25 onwards: 16 mg/kg every 4 weeks until disease progression. In combination with bortezomib, melphalan and prednisone (6-week cycle regimen): For weeks 1-6: 16 mg/kg once weekly; for weeks 7-54: 16 mg/kg every 3 weeks (total of 16 doses); for weeks 55 onwards: 16 mg/kg every 4 weeks until disease progression. In combination with bortezomib, thalidomide and dexamethasone in newly diagnosed patient eligible for autologous stem cell transplant (ASCT): Induction: For weeks 1-8: 16 mg/kg once weekly; for weeks 9-16: 16 mg/kg every 2 weeks (total of 4 doses). Consolidation (re-initiation following ASCT): 16 mg/kg every 2 weeks for 4 doses. Doses to be given via infusion at initial rate of 50 mL/hour for weeks 1-2 (1st dose may be given as single or split dose), if no reactions occur, initial rate for week 3 onwards may be given at 100 mL/hour. Rate may be increased by increments of 50 mL/hour every hour in the absence of infusion reactions. Max rate: 200 mL/hour. Pre- and post-infusion medications may be administered. Dosing interruption or discontinuation may be required according to individual safety and tolerability (refer to detailed product guideline).